Federal Judge Gives Lilly Win on Alimta Regimen Patent
June 22 2018 - 6:18PM
Dow Jones News
By Nishant Mohan
Eli Lilly & Co. said Friday that a U.S. District Court
issued a ruling protecting the patent on one of its top-selling
drugs from a competitor's product until at least 2022.
Indianapolis federal court Judge Tanya Walton Pratt ruled Dr.
Reddy's Laboratories' salt forms of pemetrexed infringed on Eli
Lilly's patent on Alimta, a pemetrexed injection. Lilly's patent
covered the administration of the chemotherapy treatment with
vitamins.
Alimta, a drug developed to treat advanced non-small cell lung
cancer, constituted about $1 billion, or 5%, of Lilly's world-wide
revenue in 2017. Alimta was the company's second-highest
revenue-generating treatment last year.
"Lilly's extensive research to discover the Alimta vitamin
regimen patent deserves intellectual property protection," Michael
Harrington, Lilly's general counsel, said in prepared remarks.
A representative for Dr. Reddy's couldn't immediately be reached
for comment.
Lilly has been cautioning investors about potentially "severe
declines in revenue" due to the expiration of patent protections on
drugs. Cialis was the company's top-selling individual drug in
2017, but it is facing expirations of two patents on the drug this
year.
Lilly shares were unchanged at $85.92 in after-hours
trading.
Write to Nishant Mohan at nishant.mohan@wsj.com
(END) Dow Jones Newswires
June 22, 2018 18:03 ET (22:03 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2023 to Apr 2024
